Clinical Trial

A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma

Study acronym: MajesTEC-7
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to compare the efficacy of teclistamab in combination with daratumumab and lenalidomide (Tec-DR) and talquetamab in combination with daratumumab and lenalidomide (Tal-DR) versus daratumumab, lenalidomide, dexamethasone (DRd).
Protocol Amendment History 1 change
notable Trial sites expanded: 265 -> 270 locations 2026-06-06
Trial Details
NCT Number NCT05552222
Lead Sponsor Janssen Research & Development, LLC
Conditions Multiple Myeloma
Enrollment 1,590 participants
Start Date 2022-10-25
Primary Completion 2031-04-30 (estimated)
Study Completion 2033-10-28 (estimated)
Updated on ClinicalTrials.gov 2026-07-06